Analysis reveals first-line treatment variations in transplant-ineligible multiple myeloma patients, suggesting important clinical considerations for frailty and comorbidity burden.
Key Points
Treatment patterns differ significantly by age and comorbidity in transplant-ineligible multiple myeloma patients.
Dexamethasone is commonly used in combination with other treatments, with frail patients often receiving simpler regimens.
Charlson Comorbidity Index plays a crucial role in predicting treatment choices for patients with multiple myeloma.
Findings may guide future clinical trials targeting frail and comorbid patient populations with multiple myeloma.